C3 glomerulonephritis associated with monoclonal gammopathy: a retrospective case series study from a single institute in China

References

• Pickering MC, D'Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079–1089.
   PubMed Web of Science ®Google Scholar
• Leung N, Rajkumar SV. Renal manifestations of plasma cell disorders. Am J Kidney Dis. 2007;50(1):155–165.
   PubMed Web of Science ®Google Scholar
• Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the international kidney and monoclonal gammopathy research group. Nat Rev Nephrol. 2019;15(1):45–59.
   PubMed Web of Science ®Google Scholar
• Leung N, Bridoux F, Hutchison CA, et al.; International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292–4295.
   PubMed Web of Science ®Google Scholar
• Bridoux F, Desport E, Frémeaux-Bacchi V, et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol. 2011;6(9):2165–2174.
   PubMed Web of Science ®Google Scholar
• Zand L, Kattah A, Fervenza FC, et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis. 2013;62(3):506–514.
   PubMed Web of Science ®Google Scholar
• Lloyd IE, Gallan A, Huston HK, et al. C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome. Clin Kidney J. 2016;9(6):794–799.
   PubMed Web of Science ®Google Scholar
• Hamzi MA, Zniber A, Badaoui GE, et al. C3 glomerulopathy associated to multiple myeloma successfully treated by autologous stem cell transplant. Indian J Nephrol. 2017;27(2):141–144.
   PubMedGoogle Scholar
• Ravindran A, Fervenza FC, Smith RJH, et al. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int. 2018;94(1):178–186.
   PubMed Web of Science ®Google Scholar
• Meri S, Koistinen V, Miettinen A, et al. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med. 1992;175(4):939–950.
   PubMed Web of Science ®Google Scholar
• Sethi S, Sukov WR, Zhang Y, et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis. 2010;56(5):977–982.
   PubMed Web of Science ®Google Scholar
• Chauvet S, Frémeaux-Bacchi V, Petitprez F, et al. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood. 2017;129(11):1437–1447.
   PubMed Web of Science ®Google Scholar
• Li LL, Li ZY, Wang SX. et al. Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis. BMC Nephrol. 2019;20(1):459–468.
   Google Scholar
• WHO, Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. 2011.
   Google Scholar
• Verdecchia P, Reboldi G, Angeli F. The 2020 international society of hypertension global hypertension practice guidelines - key messages and clinical considerations. Eur J Intern Med. 2020;82:1–6.
   PubMed Web of Science ®Google Scholar
• Servais A, Noël L-H, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82(4):454–464.
   PubMed Web of Science ®Google Scholar
• Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. 2005;16(5):1392–1403.
   PubMed Web of Science ®Google Scholar
• Sethi S, Fervenza FC, Zhang Y, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012;82(4):465–473.
   PubMed Web of Science ®Google Scholar
• Nester CM, Smith RJ. Complement inhibition in C3 glomerulopathy. Semin Immunol. 2016;28(3):241–249.
   PubMed Web of Science ®Google Scholar
• Sathick IJ, Zand L, Nasr SH, et al. Corticosteroid therapy alone for the treatment of C3 glomerulonephritis in association with monoclonal gammopathy. CN. 2019;91(2):79–86.
   Google Scholar
• Jokiranta TS, Solomon A, Pangburn MK, et al. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol. 1999;163(8):4590–4596.
   PubMed Web of Science ®Google Scholar
• Wu H, Zou HB, Xu Y, et al. Hepatitis C virus-related heat-insoluble cryoglobulinemia and thrombotic microangiopathy. Am J Med Sci. 2013;346(4):345–348.
   PubMed Web of Science ®Google Scholar
• Tan SYS, Sibley RK, Belani S, et al. Thrombotic microangiopathy with intraglomerular IgM pseudothrombi in waldenström macroglobulinemia and IgM monoclonal gammopathy. J Nephrol. 2018;31(6):907–918.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ghiringhelli Borsa N, Shao D, et al. Factor H autoantibodies and complement-mediated diseases. Front Immunol. 2020;11:607211.
   PubMed Web of Science ®Google Scholar
• Vernon KA, Ruseva MM, Cook HT, et al. Partial complement factor H deficiency associates with C3 glomerulopathy and thrombotic microangiopathy. J Am Soc Nephrol. 2016;27(5):1334–1342.
   PubMed Web of Science ®Google Scholar
• Blanc C, Togarsimalemath SK, Chauvet S, et al. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol. 2015;194(11):5129–5138.
   PubMed Web of Science ®Google Scholar
• Fermand J-P, Bridoux F, Kyle RA, et al. International Kidney and Monoclonal Gammopathy Research Group. How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 2013;122(22):3583–3590.
   PubMed Web of Science ®Google Scholar
• Haffner K, Michelfelder S, Pohl M. Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression. Pediatr Nephrol. 2015;30(11):1951–1959.
   PubMed Web of Science ®Google Scholar